Alyeska Investment Group
ARCT icon

Alyeska Investment Group’s Arcturus Therapeutics ARCT Stock Holding History

Alyeska Investment Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-102,518
Closed -$1.33M – 588
2025
Q2 		$1.33M Buy
+102,518
New +$1.21M ﹤0.01% 491
2017
Q1 		– Sell
-116,359
Closed -$1.71M – 470
2016
Q4 		$1.71M Sell
116,359
-34,938
-23% -$522K 0.01% 401
2016
Q3 		$2.62M Buy
151,297
+4,122
+3% +$133K 0.02% 371
2016
Q2 		$4.63M Sell
147,175
-2,698
-2% -$85K 0.04% 313
2016
Q1 		$3.98M Buy
149,873
+6,950
+5% +$235K 0.04% 293
2015
Q4 		$6.28M Buy
142,923
+63,584
+80% +$2.86M 0.07% 250
2015
Q3 		$3.35M Buy
+79,339
New +$4.17M 0.04% 293

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Alyeska Investment Group's ARCT Position: Q3 2025 in Review

Alyeska Investment Group sold out of Arcturus Therapeutics (ARCT) in Q3 2025, closing a stake of 102,518 shares — an estimated $1.33M sold.

Alyeska Investment Group first reported a position in ARCT in Q3 2015 and held it in 7 quarters. The position peaked at $6.28M in Q4 2015. 136 funds tracked by Wall St. Rank hold ARCT as of Q3 2025.

  • Alyeska Investment Group reported no remaining Arcturus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 102,518 Arcturus Therapeutics shares in Q3 2025, an estimated $1.33M.
  • Alyeska Investment Group first reported a position in Arcturus Therapeutics in Q3 2015 and held it in 7 quarters.
  • Alyeska Investment Group's Arcturus Therapeutics position peaked at $6.28M in Q4 2015.
  • 136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2025.

Based on Alyeska Investment Group's 13F filing for Q3 2025, filed 17 Nov 2025.